GenMark Diagnostics to Present at the Canaccord Genuity 34th Annual Growth Conference
August 06 2014 - 4:05PM
Business Wire
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of
automated, multiplex molecular diagnostic testing systems, will
present at the Canaccord Genuity 34th Annual Growth Conference to
be held at the InterContinental Boston Hotel in Boston, MA on
Wednesday, August 13, 2014. The presentation will be delivered by
Scott Mendel, Chief Financial Officer and is scheduled to begin at
9:30 a.m. Eastern Time (6:30 a.m. Pacific Time). The presentation
will be made available at http://ir.genmarkdx.com/.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics is a leading provider of automated,
multiplex molecular diagnostic testing systems that detect and
measure DNA and RNA targets to diagnose disease and optimize
patient treatment. Utilizing GenMark’s proprietary eSensor®
detection technology, GenMark’s eSensor® XT-8 system is designed to
support a broad range of molecular diagnostic tests with a compact,
easy-to-use workstation and self-contained, disposable test
cartridges. GenMark currently markets four tests that are FDA
cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory
Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity
Test. A number of other tests, including HCV Genotyping, 2C19
Genotyping, and 3A4/3A5 Genotyping are available for research use
only. For more information, visit www.genmarkdx.com.
GenMark Diagnostics, Inc.Hany MassaranyPresident/Chief Executive
Officer760-448-4358
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Apr 2023 to Apr 2024